JAZZ.NASDAQJazz Pharmaceuticals PLC
10-K/A: Jazz Pharmaceuticals Amends 2024 Annual Report on Form 10-K to Include Proxy Information
Sentiment:
Annual Report Amendment
Jazz Pharmaceuticals files an amendment to its 2024 Annual Report on Form 10-K to include information previously intended to be incorporated by reference from its proxy statement.
Summary
- Jazz Pharmaceuticals has filed an amendment to its 2024 Annual Report on Form 10-K to include information that was to be incorporated by reference from the proxy statement for the 2025 Annual General Meeting of Shareholders.
- The amendment updates information on the cover page, Part III (Items 10 through 14), and Part IV (Item 15) of the 2024 Annual Report on Form 10-K.
- New certifications by the company's principal executive officer and principal financial officer are also filed as exhibits to the amendment.
- The amendment does not modify or update other disclosures in the original report or reflect events occurring after February 26, 2025.
- As of April 15, 2025, Jazz Pharmaceuticals had 61,632,292 ordinary shares outstanding.
- Bruce Cozadd will retire as CEO by the end of 2025 and continue as Chairperson.
- The company's 2024 performance bonus program resulted in an overall corporate achievement percentage of 112% of target.
- The final payout of the 2022-2024 PSU award cycle was 66% of target due to TSR ranking.
- The company's compensation committee approved an overall corporate achievement percentage of 112% of the target corporate performance for the 2024 plan year.
Sentiment
Score: 7
Explanation: The document presents a generally positive outlook with strong revenue growth in key products and strategic initiatives. However, there are some negative aspects such as the reduced PSU payout and a late filing, which temper the overall sentiment.
Positives
- Xywav net product sales increased by 16% to $1,473.2 million in 2024.
- Epidiolex/Epidyolex net product sales increased by 15% to $972.4 million in 2024.
- Rylaze/Enrylaze net product sales increased by 4% to $410.8 million in 2024.
- Zepzelca net product sales increased by 11% to $320.3 million in 2024.
- Ziihera was launched in the U.S. for treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) BTC in December 2024.
- Approximately 91% of votes cast at the 2024 annual meeting were in favor of the compensation of named executive officers.
Negatives
- The 2022-2024 PSU award cycle payout was reduced to 66% of target due to TSR ranking in the 43rd percentile against peers.
- A late filing of one Form 4 to report 1,410 shares sold in September 2024 by Liz Henderson due to an inadvertent administrative error.
Risks
- The document contains forward-looking statements that are subject to risks, uncertainties, and other factors that may cause actual results to differ materially.
- The company's future results may be materially different from what they expect.
Future Outlook
The company's strategy for growth is rooted in executing commercial launches and ongoing commercialization initiatives; advancing robust R&D programs and delivering impactful clinical results; effectively deploying capital to strengthen the prospects of achieving our shortand long-term goals through strategic corporate development; and delivering strong financial performance.
Management Comments
- Bruce C. Cozadd notified the Board of his intent to retire from his role as CEO upon the selection and appointment of the Company's next CEO by the end of 2025.
Industry Context
The document mentions consolidation in the biopharmaceutical industry as a factor influencing severance benefits for executives.
Comparison to Industry Standards
- The compensation committee uses a peer group of 13 companies in the life sciences industry to benchmark executive compensation.
- The peer group includes Alkermes plc, Gilead Sciences, Inc., Organon & Co., Vertex Pharmaceuticals Incorporated, Biogen Inc., Horizon Therapeutics plc, Regeneron Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Incyte Corporation, Seagen Inc., Exelixis, Inc., Neurocrine Biosciences, Inc., and United Therapeutics Corporation.
- The company's relative TSR is compared against the Nasdaq Biotechnology Index for PSU awards.
- The company aims to provide a competitive compensation program for its non-employee directors, benchmarked against the same peer group used for executive compensation.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| CEO | Bruce C. Cozadd | TBD | End of 2025 | Retirement |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Clawback Policy | In November 2023, the compensation committee adopted the Clawback Policy, that complies with the new listing standards adopted by Nasdaq that implement the new SEC rules under the Dodd-Frank Wall Street Reform and Consumer Protection Act and applies to our executive officers | October 2, 2023 | Requires the company to recover from covered executive officers the amount of erroneously awarded compensation resulting from an accounting restatement due to the material noncompliance of the company with any financial reporting requirement under the securities laws. |
| Executive Committee Severance Benefit Plan | Effective April 23, 2025 we adopted an Executive Committee Severance Benefit Plan, or the severance plan. All of our NEOs for 2024 other than Mr. Cozadd and Ms. Carr are eligible for certain severance benefits under our severance plan. | April 23, 2025 | Provides for benefits upon an involuntary termination that does not occur upon or within twelve months following a change in control. |
Legal Proceedings
- A preliminary settlement agreement was reached in a class action lawsuit.
Related Party Transactions
- A family member of Class I director Laura J. Hamill is employed by our company, with total compensation of approximately $416,000 for fiscal year 2024.
Stakeholder Impact
- Shareholders: The amendment provides updated information on executive compensation and corporate governance, which is relevant to shareholder voting decisions.
- Employees: The document discusses compensation policies and benefit plans, which directly impact employees.
- Customers: The document highlights the performance of key products, which are relevant to customers and patients.
- Investors: The document provides financial information and forward-looking statements, which are important for investment decisions.
Next Steps
- The company will continue outreach and dialogue with its shareholders in 2025.
- The board of directors will select and appoint the company's next CEO by the end of 2025.
Key Dates
| Date | Description |
|---|---|
| January 18, 2012 | The businesses of Jazz Pharmaceuticals, Inc. and Azur Pharma were combined in a merger transaction. |
| December 2011 | The 2011 Plan was adopted by Jazz Pharmaceuticals, Inc.'s board of directors and approved by Jazz Pharmaceuticals, Inc.'s stockholders in connection with their approval of the Azur Merger. |
| May 2021 | Jazz Pharmaceuticals acquired GW Pharmaceuticals plc. |
| November 2023 | The compensation committee adopted an incentive compensation recoupment policy. |
| December 31, 2024 | Fiscal year ended. |
| February 26, 2025 | Original 2024 Annual Report on Form 10-K was filed with the SEC. |
| April 15, 2025 | A total of 61,632,292 ordinary shares of the registrant were outstanding. |
| April 22, 2025 | Date for director and executive officer information. |
| April 23, 2025 | Effective date of Executive Committee Severance Benefit Plan. |
| End of 2025 | Bruce C. Cozadd to retire as CEO. |
Keywords
Jazz Pharmaceuticals, Annual Report, Form 10-K, Executive Compensation, Amendment, Financial Performance, Directors, Shareholders, Pharmaceuticals, Revenue, PSU, RSU, Pipeline, Oncology, Neuroscience
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.